MARK WILKOWSKI: Open Payments
NPI 1164479150 · CHEEKTOWAGA, NY. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$911 in 48 payments from 16 companies in 2025. Trend: 2023 $0 · 2024 $531 · 2025 $911
Food & beverage: $911
| Company | Payments | Amount |
|---|---|---|
| Novo Nordisk Inc | 12 | $189 |
| AstraZeneca Pharmaceuticals LP | 9 | $162 |
| GlaxoSmithKline, LLC. | 5 | $91 |
| Boston Scientific Corporation | 2 | $74 |
| Exact Sciences Corporation | 3 | $63 |
| Insulet Corporation | 2 | $44 |
| Amneal Pharmaceuticals LLC | 2 | $42 |
| Merck Sharp & Dohme LLC | 2 | $41 |
| Lilly USA, LLC | 2 | $39 |
| Corcept Therapeutics | 2 | $35 |
Products named: TRELEGY ELLIPTA, WATCHMAN, FARXIGA, Cologuard Collection Kit, AIRSUPRA, Wegovy, Omnipod, UNITHROID.
Industry payments across NY — which companies pay providers there.
